Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...
Akeso Reported 2021 Annual Results
Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology,...
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the IND...
Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer
HONG KONG, March 2, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwidetoday announced that it has entered into a collab...
AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)
HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody (research and development code: AK115) injection developed in-house by the Company, has obtained approval from the Centre fo...
AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and Ivonescimab (PD-1/VEGF bi-specific antibody, research and devel...
AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was dosed in a Phase III registrational clinical trial of the Company's novel immuno-oncology drug, Ivonescimab (PD-1/VEGF bi-specific antibody, AK112), combined with chemotherapy versus placebo combin...
Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors
HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 monoclonal antibody, research and development code: AK117), the novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody, research an...
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (PD-1/CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody), the novel immuno-o...
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER
HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Today, Akeso (09926.HK) announces that Cadonilimab (PD-1/ CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with concurrent chemoradiotherapy obtained approval from the Center for Dru...
Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS
HONG KONG, Dec. 27, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed. Such clinical trial aims to evalua...
Akeso's PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA
HONG KONG, Dec. 22, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (PCSK9 monoclonal antibody, research and development code: AK102), jointly developed by the Company and Dawnrays Biotechnology Capital (Asia) Ltd., completed patient enrollment early in a pivotal re...
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
HONG KONG, Dec. 6, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendo...
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Ad...
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 24, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced that the anti PD-1 monoclonal antibody drugPenpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited (stock code: 1177.HK), has obtained marketing appr...
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK) is pleased to announce today that, Akesohas been awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published byInstitutional Investor, and has been ranked top 3 in all...
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States
HONG KONG, May 24, 2021 /PRNewswire/ -- On May 24, 2021, Akeso, Inc. (HKEx: 9926.HK) announced that Penpulimab (research and development code: AK105), an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited (HKEx: 1177.HK), has submitted a Biologics Licens...
